Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.

Terese Hylander, Olivia Larsson, Ulla Westin, Mia Eriksson, Susanna Kumlien Georén, Ola Winqvist, Lars-Olaf Cardell

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Allergen-specific immunotherapy represents the only disease-modifying treatment for allergic diseases. We and others have previously demonstrated that intralymphatic immunotherapy (ILIT), a less time-consuming alternative to conventional subcutaneous immunotherapy (SCIT), is safe and effective. However, this has recently been disputed. The aim of this study was therefore to expand our previous trial, further assessing the safety and efficacy of ILIT.
    Original languageEnglish
    Article number10
    JournalRespiratory Research
    Volume17
    Issue number1
    DOIs
    Publication statusPublished - 2016

    Subject classification (UKÄ)

    • Respiratory Medicine and Allergy

    Fingerprint

    Dive into the research topics of 'Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.'. Together they form a unique fingerprint.

    Cite this